## ACCELERATING ACCESS TO EBOLA VACCINES AND COUNTRY PERSPECTIVE

BOARD MEETING Seth Berkley, Robert Newman, Aurélia Nguyen 10-11 December 2014, Geneva




## AGENDA

- **1** Process of generating Board recommendation
- **2** Funding landscape and Gavi capabilities
- **3** Four recommended areas for Gavi action
- **4** Financial implications
- **6** Risks




## 8-WEEK PROCESS TO GENERATE A BOARD RECOMMENDATION ON EBOLA RESPONSE



## WHERE CAN GAVI CONTRIBUTE? PARTNER LANDSCAPING AND GAVI CAPABILITY ASSESSMENT

Cost category		Critical funding area	Est. funding coverage	Fit with Gavi capabilities? (based on past experience, partner input)
Clinical trials		Phase I	High	×
		Phase II	High	×
		Phase III	High	×
Production & procurement	Production scale up	Production at clinical trial scale	High	×
		Scale up / scale optimisation	Medium	
		Commercial scale mfg	Low	
	Procurement	Vaccine procurement	Medium	
	<b>Risk mitigation</b>	Indemnification	Medium	×
	Diverted manufacturer resources	Diverted manufacturer resources	Low	✓
Vaccine roll-out		Planning & coordination, social mobilisation, IEC, training, HR, transport /logistics/cold chain, waste management, surveillance and monitoring of AEFI, etc.	Medium	✓
		Clinical trials	Low	×
Future outbreak preparedness		Production scale up	Low	
		Procurement	Low	$\checkmark$
		Vaccine roll-out	Low	

## **4 RECOMMENDED AREAS FOR GAVI ACTION**





## 1 VACCINE PRODUCTION AND PROCUREMENT ENVELOPE DRIVEN BY LEVEL OF UNCERTAINTY AND EVOLVING LANDSCAPE

Procurement-related principles

Plan for high vaccine demand

Focus on alleviating bottlenecks to vaccine availability

Prioritise solutions that are candidate-agnostic

Avoid prematurely locking into a market that is not fully understood

**Recommendation:** Envelope signaling Gavi potential spend

Utilises Gavi's multilateral mechanism to aggregate and coordinate funding

Signals a market for Ebola vaccine and related supplies

Allows addressing of different demand scenarios in an evolving environment

Enables tailored agreements with individual manufacturers

Enables support of multiple manufacturers



3

## 1 VACCINE PRODUCTION AND PROCUREMENT DETERMINATION OF ENVELOPE SIZE

### Key drivers of size of US \$300 million envelope

# Key drivers of uncertainty around spend within envelope

Volume of vaccine required to combat current outbreak	Up to 12M courses	Actual demand versus "high demand" scenario	Actual demand anywhere from <100K to >12M courses
Number of manufacturers	2-3 manufacturers (with different economics)	Manufacturer from which vaccines are ultimately procured	Different cost structures, vaccine technologies
Manufacturer costs	Marginal costs of production and unsubsidized scale up costs	Level of subsidy for each manufacturer	Funding discussions still evolving

Funding structures within this envelope will be subject to EC approval



## 2 FUNDING VACCINE ROLL-OUT BASED ON CURRENT DATA – DETAILED COUNTRY-LEVEL COSTING UNDERWAY

### A Standard campaign categories with Ebola-specific

cost multiplier assigned

- Social mobilisation, IEC<sup>1</sup>, advocacy
- HR and training
- Vehicles and transportation
- Waste management
- Surveillance, including for AEFI<sup>2</sup>
- Evaluation

- B Additional cost categories for Ebola vaccine roll-out
- Emergency Operations Centres
- Cold chain and logistics
- Security and crowd control
- Increased infection control measures

- Stockpile cost categories
- Management of stockpile
- Operational costs for use of stockpiled courses in future outbreaks

US\$ 38 M <sup>3</sup> US\$ 7 M US\$ 45 M





#### Board meeting 10-11 December 2014

# **3** FUTURE OUTBREAK PREPAREDNESS

Recommendation 1: Stockpile of firstgeneration vaccines

- Relatively small stockpile required
- To be maintained until 2nd generation vaccine becomes available

Gaps remaining

Profile of first generation vaccine(s) expected to be suboptimal for longer-term application:

- Monovalent vaccine
- Thermostability concerns

Recommendation 2: In-principle commitment to 2nd-generation stockpile


- Assure availability of effective vaccines for future outbreaks
- Vaccine availability dependent on timing of vaccine development and optimisation

Lack of longer-term availability of an effective Ebola vaccine could result in a repeat of the current situation



# RECOVERY OF HEALTH AND IMMUNISATION SYSTEMS

Ebola has crippled health and immunisation systems



**Recommendations to support recovery** 

(Upon country request)

Vaccines and related injection safety devices and programmatic support	up to US\$ 12.5 M
Reprogramming of currently approved HSS grants	No additional costs
Increase of HSS funding	up to US\$ 30.5 M
Waiving of 2014-15 co-financing requirements	up to <b>US\$ 2 M</b>
Total	up to <b>US\$ 45 M</b>



1. Coverage with 3rd dose of a DTP-containing vaccine

## FINANCIAL IMPLICATIONS OF APPROVING RECOMMENDATIONS

Recommendation per Board Paper	US\$ million			
Ebola Programme Funding Envelope (2015-2020)				
Ebola vaccine production and procurement	300			
Ebola vaccine roll-out	45			
Recovery of health and immunisation systems	45			
Sub-total: Ebola Programme Funding Envelope	up to 390			
Addition to Business Plan budget (2015-2016)				
Secretariat costs	3.5			
Support to WHO & UNICEF	7.0			
Support to Civil Society Organisations	0.5			
Sub-total: Addition to Business Plan Budget	up to 11.0			
Total cost of funding the recommendations	up to 401			
Less: Already provided in Gavi expenditure forecast for 2014-2015	(100)			
Additional resources required	up to 301			
Deduct: Resources from other funding agencies / donors	TBD			
Balance to be funded through Gavi	TBD			
10 Board meeting 10-11 December 2014				



# **RISKS ASSOCIATED WITH RECOMMENDATIONS**

Risk	Potential mitigation(s)	
Vaccine safety & acceptability not fully evaluated	<ul> <li>Regulatory advice, WHO recommendation for use</li> <li>Information to countries</li> </ul>	
Gavi investments have no impact on current outbreak	<ul> <li>Gavi investments contingent on WHO recommendation for use</li> </ul>	
Gavi enters into sub-optimal agreements with manufacturers	<ul> <li>Short-term agreements guided by WHO recommendations</li> <li>Allow adjustments as situation evolves</li> <li>Manufacturer transparency</li> </ul>	
Vaccines do not reach target populations	<ul> <li>Support health system recovery efforts</li> <li>Plan carefully for vaccine roll out, commit sufficient funding for critical activities</li> </ul>	
Gavi ill-suited to engage in emergency response	<ul> <li>Leverage existing Gavi mechanisms wherever possible</li> </ul>	
Human resource diversion hinders performance of other Gavi efforts	<ul> <li>Reprioritise current staff workloads</li> <li>Hire dedicated staff to manage Ebola-related activities</li> </ul>	
Financial resource diversion hinders performance of other Gavi efforts	<ul> <li>Seek incremental funding for Ebola activities from donors who have already pledged resources for Ebola response</li> </ul>	



1. See Section 4.2 of Board Paper for more details





www.gavi.org